Extracellular molecules involved in cancer cell invasion

Cancers

Volumn 7, Issue 1, 2015, Pages 238-265

  Stivarou, Theodora ^a   Patsavoudi, Evangelia ^a,b  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

^b UNIVERSITY OF WEST ATTICA   (Greece)

Author keywords

Cell invasion; Cell surface; Extracellular; Metastasis

Indexed keywords

AMPHIREGULIN; CELL CYCLE PROTEIN 37; CHAPERONE; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; DENTIN MATRIX PROTEIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBRONECTIN; GELATINASE A; GELATINASE B; GROWTH FACTOR; HEAT SHOCK PROTEIN 90; HERMES ANTIGEN; HYALURONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; NEU DIFFERENTIATION FACTOR; NOTCH RECEPTOR; OSTEOPONTIN; P21 ACTIVATED KINASE 1; RAF PROTEIN; RAS PROTEIN; SCLEROPROTEIN; SIALOPROTEIN; SONIC HEDGEHOG PROTEIN; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

CANCER CELL; CANCER STEM CELL; CANCER SURVIVAL; CELL INVASION; CELL MOTILITY; CELL SURFACE; EXTRACELLULAR MATRIX; METASTASIS; OVERALL SURVIVAL; POSITIVE FEEDBACK; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84921917004     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers7010238     Document Type: Review

References (190)

1. Mehlen, P.; Puisieux, A. Metastasis: A question of life or death. Nat. Rev. Cancer 2006, 6, 449–458.
2. Monteiro, J.; Fodde, R. Cancer stemness and metastasis: Therapeutic consequences and perspectives. Eur J. Cancer 2010, 46, 1198–1203.
3. Nguyen, D.X.; Bos, P.D.; Massague, J. Metastasis: From dissemination to organ-specific colonization. Nat. Rev. Cancer 2009, 9, 274–284.
4. Liao, W.T.; Ye, Y.P.; Deng, Y.J.; Bian, X.W.; Ding, Y.Q. Metastatic cancer stem cells: From the concept to therapeutics. Am. J. Stem. Cells 2014, 3, 46–62.
5. Spano, D.; Heck, C.; de Antonellis, P.; Christofori, G.; Zollo, M. Molecular networks that regulate cancer metastasis. Semin. Cancer Biol. 2012, 22, 234–249.
6. Olivotto, M.; Dello Sbarba, P. Environmental restrictions within tumor ecosystems select for a convergent, hypoxia-resistant phenotype of cancer stem cells. Cell Cycle 2008, 7, 176–187.
7. Baumann, M.; Krause, M.; Hill, R. Exploring the role of cancer stem cells in radioresistance. Nat. Rev. Cancer 2008, 8, 545–554.
8. Fabian, A.; Barok, M.; Vereb, G.; Szollosi, J. Die hard: Are cancer stem cells the bruce willises of tumor biology? Cytometry A 2009, 75, 67–74.
9. Li, F.; Tiede, B.; Massague, J.; Kang, Y. Beyond tumorigenesis: Cancer stem cells in metastasis. Cell Res. 2007, 17, 3–14.
10. Dreesen, O.; Brivanlou, A.H. Signaling pathways in cancer and embryonic stem cells. Stem. Cell Rev. 2007, 3, 7–17.
11. Toole, B.P. Hyaluronan: From extracellular glue to pericellular cue. Nat. Rev. Cancer 2004, 4, 528–539.
12. Jaracz, S.; Chen, J.; Kuznetsova, L.V.; Ojima, I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg. Med. Chem. 2005, 13, 5043–5054.
13. Gotte, M.; Yip, G.W. Heparanase, hyaluronan, and CD44 in cancers: A breast carcinoma perspective. Cancer Res. 2006, 66, 10233–10237.
14. Udabage, L.; Brownlee, G.R.; Nilsson, S.K.; Brown, T.J. The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp. Cell Res. 2005, 310, 205–217.
15. Gould, V.E.; Koukoulis, G.K.; Virtanen, I. Extracellular matrix proteins and their receptors in the normal, hyperplastic and neoplastic breast. Cell Differ. Dev. 1990, 32, 409–416.
16. Hong, H.; Zhou, T.; Fang, S.; Jia, M.; Xu, Z.; Dai, Z.; Li, C.; Li, S.; Li, L.; Zhang, T.; et al. Pigment epithelium-derived factor (PEDF) inhibits breast cancer metastasis by down-regulating fibronectin. Breast Cancer Res. Treat. 2014, 148, 61–72.
17. Hunter, M.C.; O’Hagan, K.L.; Kenyon, A.; Dhanani, K.C.; Prinsloo, E.; Edkins, A.L. Hsp90 binds directly to fibronectin (FN) and inhibition reduces the extracellular fibronectin matrix in breast cancer cells. PLOS ONE 2014, 9, e86842.
18. Ioachim, E.; Charchanti, A.; Briasoulis, E.; Karavasilis, V.; Tsanou, H.; Arvanitis, D.L.; Agnantis, N.J.; Pavlidis, N. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: Their prognostic value and role in tumour invasion and progression. Eur. J. Cancer 2002, 38, 2362-2370.
19. Mao, Y.; Schwarzbauer, J.E. Fibronectin fibrillogenesis, a cell-mediated matrix assembly process. Matrix Biol. 2005, 24, 389-399.
20. Robinson, E.E.; Foty, R.A.; Corbett, S.A. Fibronectin matrix assembly regulates a5p1-mediated cell cohesion. Mol. Biol. Cell 2004, 15, 973-981.
21. Wierzbicka-Patynowski, I.; Schwarzbauer, J.E. The ins and outs of fibronectin matrix assembly. J. Cell Sci. 2003, 116, 3269-3276.
22. Bae, Y.K.; Kim, A.; Kim, M.K.; Choi, J.E.; Kang, S.H.; Lee, S.J. Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer. Hum. Pathol. 2013, 44, 2028-2037.
23. Das, S.; Banerji, A.; Frei, E.; Chatterjee, A. Rapid expression and activation of MMP-2 and MMP-9 upon exposure of human breast cancer cells (MCF-7) to fibronectin in serum free medium. Life Sci. 2008, 82, 467-476.
24. Maity, G.; Choudhury, P.R.; Sen, T.; Ganguly, K.K.; Sil, H.; Chatterjee, A. Culture of human breast cancer cell line (MDA-MB-231) on fibronectin-coated surface induces pro-matrix metalloproteinase-9 expression and activity. Tumour Biol. 2011, 32, 129-138.
25. Fisher, L.W.; Jain, A.; Tayback, M.; Fedarko, N.S. Small integrin binding ligand n-linked glycoprotein gene family expression in different cancers. Clin. Cancer Res. 2004, 10, 8501-8511.
26. Wai, P.Y.; Kuo, P.C. Osteopontin: Regulation in tumor metastasis. Cancer Metastasis Rev. 2008, 27, 103-118.
27. Bellahcene, A.; Castronovo, V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am. J. Pathol. 1995, 146, 95-100.
28. Brown, L.F.; Papadopoulos-Sergiou, A.; Berse, B.; Manseau, E.J.; Tognazzi, K.; Perruzzi, C.A.; Dvorak, H.F.; Senger, D.R. Osteopontin expression and distribution in human carcinomas. Am. J. Pathol. 1994, 145, 610-623.
29. Casson, A.G; Wilson, S.M.; McCart, J.A.; O’Malley, F.P.; Ozcelik, H.; Tsao, M.S.; Chambers, A.F. Ras mutation and expression of the ras-regulated genes osteopontin and cathepsin l in human esophageal cancer. Int. J. Cancer 1997, 72, 739-745.
30. Gotoh, M.; Sakamoto, M.; Kanetaka, K.; Chuuma, M.; Hirohashi, S. Overexpression of osteopontin in hepatocellular carcinoma. Pathol. Int. 2002, 52, 19-24.
31. Hirota, S.; Ito, A.; Nagoshi, J.; Takeda, M.; Kurata, A.; Takatsuka, Y.; Kohri, K.; Nomura, S.; Kitamura, Y. Expression of bone matrix protein messenger ribonucleic acids in human breast cancers. Possible involvement of osteopontin in development of calcifying foci. Lab. Invest. 1995, 72, 64-69.
32. Senger, D.R.; Perruzzi, C.A.; Gracey, C.F.; Papadopoulos, A.; Tenen, D.G. Secreted phosphoproteins associated with neoplastic transformation: Close homology with plasma proteins cleaved during blood coagulation. Cancer Res. 1988, 48, 5770-5774.
33. Singhal, H.; Bautista, D.S.; Tonkin, K.S.; O’Malley, F.P.; Tuck, A.B.; Chambers, A.F.; Harris, J.F. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin. Cancer Res. 1997, 3, 605-611.
34. Tuck, A.B.; O’Malley, F.P.; Singhal, H.; Harris, J.F.; Tonkin, K.S.; Kerkvliet, N.; Saad, Z.; Doig, G.S.; Chambers, A.F. Osteopontin expression in a group of lymph node negative breast cancer patients. Int. J. Cancer 1998, 79, 502-508.
35. Bramwell, V.H.; Doig, G.S.; Tuck, A.B.; Wilson, S.M.; Tonkin, K.S.; Tomiak, A.; Perera, F.; Vandenberg, T.A.; Chambers, A.F. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin. Cancer Res. 2006, 12, 3337-3343.
36. Chang, Y.S.; Kim, H.J.; Chang, J.; Ahn, CM.; Kim, S.K. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 2007, 57, 373-380.
37. Angelucci, A.; Festuccia, C; D’Andrea, G; Teti, A.; Bologna, M. Osteopontin modulates prostate carcinoma invasive capacity through rgd-dependent upregulation of plasminogen activators. Biol Chem. 2002, 383, 229-234.
38. Furger, K.A.; Allan, A.L.; Wilson, S.M.; Hota, C; Vantyghem, S.A.; Postenka, CO.; Al-Katib, W.; Chambers, A.F.; Tuck, A.B. Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol. Cancer Res. 2003, 1, 810-819.
39. Senger, D.R.; Perruzzi, C.A. Cell migration promoted by a potent grgds-containing thrombin-cleavage fragment of osteopontin. Biochim. Biophys. Acta 1996, 1314, 13-24.
40. Chen, Y.J.; Wei, Y.Y.; Chen, H.T.; Fong, Y.C.; Hsu, C.J.; Tsai, C.H.; Hsu, H.C; Liu, S.H.; Tang, C.H. Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. J. Cell Physiol. 2009, 221, 98-108.
41. Arap, W.; Pasqualini, R.; Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998, 279, 377-380.
42. Bayless, K.J.; Salazar, R.; Davis, G.E. RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the αvβ3 and α5β1 integrins. Am. J. Pathol. 2000, 156, 1673-1683.
43. Brooks, P.C; Montgomery, A.M.; Rosenfeld, M.; Reisfeld, R.A.; Hu, T.; Klier, G; Cheresh, D.A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79, 1157-1164.
44. Scatena, M.; Almeida, M.; Chaisson, M.L.; Fausto, N.; Nicosia, R.F.; Giachelli, CM. NF-kappaB mediates αvβ3 integrin-induced endothelial cell survival. J. Cell Biol. 1998, 141, 1083-1093.
45. Senger, D.R; Ledbetter, S.R; Claffey, K.P.; Papadopoulos-Sergiou, A.; Peruzzi, C.A.; Detmar, M. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the αvβ3 integrin, osteopontin, and thrombin. Am. J. Pathol. 1996, 149, 293-305.
46. Asosingh, K.; Gunthert, U.; Bakkus, M.H.; de Raeve, H.; Goes, E.; van Riet, I.; van Camp, B.; Vanderkerken, K. In vivo induction of insulin-like growth factor-I receptor and CD44V6 confers homing and adhesion to murine multiple myeloma cells. Cancer Res. 2000, 60, 3096–3104.
47. Goodison, S.; Urquidi, V.; Tarin, D. CD44 cell adhesion molecules. Mol. Pathol. 1999, 52, 189–196.
48. Gunthert, U.; Hofmann, M.; Rudy, W.; Reber, S.; Zoller, M.; Haussmann, I.; Matzku, S.; Wenzel, A.; Ponta, H.; Herrlich, P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991, 65, 13–24.
49. Ponta, H.; Sherman, L.; Herrlich, P.A. CD44: From adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell Biol. 2003, 4, 33–45.
50. Rudzki, Z.; Jothy, S. CD44 and the adhesion of neoplastic cells. Mol. Pathol. 1997, 50, 57–71.
51. Takahashi, K.; Takahashi, F.; Hirama, M.; Tanabe, K.K.; Fukuchi, Y. Restoration of CD44S in non-small cell lung cancer cells enhanced their susceptibility to the macrophage cytotoxicity. Lung Cancer 2003, 41, 145–153.
52. Sangaletti, S.; Tripodo, C.; Sandri, S.; Torselli, I.; Vitali, C.; Ratti, C.; Botti, L.; Burocchi, A.; Porcasi, R.; Tomirotti, A.; et al. Osteopontin shapes immunosuppression in the metastatic niche. Cancer Res. 2014, 74, 4706–4719.
53. Zaidel-Bar, R.; Itzkovitz, S.; Ma’ayan, A.; Iyengar, R.; Geiger, B. Functional atlas of the integrin adhesome. Nat. Cell Biol. 2007, 9, 858–867.
54. Takagi, J.; Strokovich, K.; Springer, T.A.; Walz, T. Structure of integrin alpha5beta1 in complex with fibronectin. Embo J. 2003, 22, 4607–4615.
55. Giancotti, F.G.; Ruoslahti, E. Integrin signaling. Science 1999, 285, 1028–1032.
56. Berrier, A.L.; Yamada, K.M. Cell-matrix adhesion. J. Cell Physiol. 2007, 213, 565–573.
57. Keller, E.T.; Brown, J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J. Cell Biochem. 2004, 91, 718–729.
58. Ganguly, K.K.; Pal, S.; Moulik, S.; Chatterjee, A. Integrins and metastasis. Cell Adh. Migr. 2013, 7, 251–261.
59. Hosotani, R.; Kawaguchi, M.; Masui, T.; Koshiba, T.; Ida, J.; Fujimoto, K.; Wada, M.; Doi, R.; Imamura, M. Expression of integrin alphavbeta3 in pancreatic carcinoma: Relation to MMP-2 activation and lymph node metastasis. Pancreas 2002, 25, e30–e35.
60. Takayama, S.; Ishii, S.; Ikeda, T.; Masamura, S.; Doi, M.; Kitajima, M. The relationship between bone metastasis from human breast cancer and integrin alpha(v)beta3 expression. Anticancer Res. 2005, 25, 79–83.
61. Ricono, J.M.; Huang, M.; Barnes, L.A.; Lau, S.K.; Weis, S.M.; Schlaepfer, D.D.; Hanks, S.K.; Cheresh, D.A. Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer Res. 2009, 69, 1383–1391.
62. Berner, H.S.; Suo, Z.; Risberg, B.; Villman, K.; Karlsson, M.G.; Nesland, J.M. Clinicopathological associations of CD44 mrna and protein expression in primary breast carcinomas. Histopathology 2003, 42, 546–554.
63. Diaz, L.K.; Zhou, X.; Wright, E.T.; Cristofanilli, M.; Smith, T.; Yang, Y.; Sneige, N.; Sahin, A.; Gilcrease, M.Z. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin. Cancer Res. 2005, 11, 3309–3314.
64. Rys, J.; Kruczak, A.; Lackowska, B.; Jaszcz-Gruchala, A.; Brandys, A.; Stelmach, A.; Reinfuss, M. The role of CD44V3 expression in female breast carcinomas. Pol. J. Pathol. 2003, 54, 243–247.
65. Hiscox, S.; Baruha, B.; Smith, C.; Bellerby, R.; Goddard, L.; Jordan, N.; Poghosyan, Z.; Nicholson, R.I.; Barrett-Lee, P.; Gee, J. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. BMC Cancer 2012, doi:10.1186/1471-2407-1112-1458.
66. Bapat, S.A. Human ovarian cancer stem cells. Reproduction 2010, 140, 33–41.
67. Du, L.; Wang, H.; He, L.; Zhang, J.; Ni, B.; Wang, X.; Jin, H.; Cahuzac, N.; Mehrpour, M.; Lu, Y.; Chen, Q. CD44 is of functional importance for colorectal cancer stem cells. Clin. Cancer Res. 2008, 14, 6751–6760.
68. Jaggupilli, A.; Elkord, E. Significance of CD44 and CD24 as cancer stem cell markers: An enduring ambiguity. Clin. Dev. Immunol. 2012, doi:10.1155/2012/708036.
69. Wang, R.; Lv, Q.; Meng, W.; Tan, Q.; Zhang, S.; Mo, X.; Yang, X. Comparison of mammosphere formation from breast cancer cell lines and primary breast tumors. J. Thorac. Dis. 2014, 6, 829–837.
70. Buck, M.B.; Knabbe, C. TGF-beta signaling in breast cancer. Ann. N. Y. Acad. Sci. 2006, 1089, 119–126.
71. Mu, Y.; Gudey, S.K.; Landstrom, M. Non-smad signaling pathways. Cell Tissue Res. 2012, 347, 11–20.
72. Vogelmann, R.; Nguyen-Tat, M.D.; Giehl, K.; Adler, G.; Wedlich, D.; Menke, A. TGFbeta-induced downregulation of E-cadherin-based cell-cell adhesion depends on PI3-kinase and pten. J. Cell Sci. 2005, 118, 4901–4912.
73. Roberts, A.B. Molecular and cell biology of TGF-beta. Miner. Electrolyte MeTable 1998, 24, 111–119.
74. Massague, J. TGFbeta in cancer. Cell 2008, 134, 215–230.
75. Miyazono, K. Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of Cancer. Proc. Jpn. Acad. B Phys. Biol. Sci. 2009, 85, 314–323.
76. Xu, J.; Lamouille, S.; Derynck, R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009, 19, 156–172.
77. ten Dijke, P.; Goumans, M.J.; Pardali, E. Endoglin in angiogenesis and vascular diseases. Angiogenesis. 2008, 11, 79–89.
78. Drabsch, Y.; ten Dijke, P. TGF-beta signaling in breast cancer cell invasion and bone metastasis. J. Mammary Gland Biol. Neoplasia 2011, 16, 97–108.
79. Flavell, R.A.; Sanjabi, S.; Wrzesinski, S.H.; Licona-Limon, P. The polarization of immune cells in the tumour environment by TGFbeta. Nat. Rev. Immunol. 2010, 10, 554–567.
80. Inman, G.J. Switching TGFbeta from a tumor suppressor to a tumor promoter. Curr. Opin. Genet. Dev. 2011, 21, 93–99.
81. Principe, D.R.; Doll, J.A.; Bauer, J.; Jung, B.; Munshi, H.G.; Bartholin, L.; Pasche, B.; Lee, C.; Grippo, P.J. TGF-beta: Duality of function between tumor prevention and carcinogenesis. J. Natl. Cancer Inst. 2014, doi:10.1093/jnci/djt1369.
82. Morrison, CD.; Parvani, J.G.; Schiemann, W.P. The relevance of the TGF-beta paradox to EMT-MET programs. Cancer Lett. 2013, 341, 30-40.
83. Zhang, Q.; Yu, N.; Lee, C. Mysteries of TGF-beta paradox in benign and malignant cells. Front. Oncol. 2014, doi:10.3389/fonc.2014.00094.
84. Zhang, Q.; Yu, N.; Lee, C. Vicious cycle of TGF-beta signaling in tumor progression and metastasis. Am. J. Clin. Exp. Urol. 2014, 2, 149-155.
85. Garratt, A.N. “To erb-b or not to erb-b…” Neuregulin-1/erbb signaling in heart development and function. J. Mol. Cell Cardiol. 2006, 41, 215-218.
86. Chang, H.; Riese, D.J., 2nd; Gilbert, W.; Stern, D.F.; McMahan, U.J. Ligands for erbb-family receptors encoded by a neuregulin-like gene. Nature 1997, 387, 509-512.
87. Harari, D.; Tzahar, E.; Romano, J.; Shelly, M.; Pierce, J.H.; Andrews, G.C.; Yarden, Y. Neuregulin-4: A novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene 1999, 18, 2681-2689.
88. Holmes, W.E.; Sliwkowski, M.X.; Akita, R.W.; Henzel, W.J.; Lee, J.; Park, J.W.; Yansura, D.; Abadi, N.; Raab, H.; Lewis, G.D. et al. Identification of heregulin, a specific activator of p185erbb2. Science 1992, 256, 1205-1210.
89. Zhang, D.; Sliwkowski, M.X.; Mark, M.; Frantz, G; Akita, R.; Sun, Y.; Hillan, K.; Crowley, C; Brush, J.; Godowski, P.J. Neuregulin-3 (NRG3): A novel neural tissue-enriched protein that binds and activates ErbB4. Proc. Natl. Acad. Sci. USA 1997, 94, 9562-9567.
90. Carraway, K.L., 3rd; Sliwkowski, M.X.; Akita, R.; Platko, J.V.; Guy, P.M.; Nuijens, A.; Diamonti, A.J.; Vandlen, R.L.; Cantley, L.C.; Cerione, R.A. The ErbB3 gene product is a receptor for heregulin. J. Biol. Chem. 1994, 269, 14303-14306.
91. Stove, C; Bracke, M. Roles for neuregulins in human Cancer. Clin. Exp. Metastasis. 2004, 21, 665-684.
92. Esper, R.M.; Pankonin, M.S.; Loeb, J.A. Neuregulins: Versatile growth and differentiation factors in nervous system development and human disease. Brain Res. Rev. 2006, 51, 161-175.
93. Falls, D.L. Neuregulins and the neuromuscular system: 10 years of answers and questions. J. Neurocytol. 2003, 32, 619-647.
94. Li, L.; Cleary, S.; Mandarano, M.A.; Long, W.; Birchmeier, C; Jones, F.E. The breast proto-oncogene, hrgalpha regulates epithelial proliferation and lobuloalveolar development in the mouse mammary gland. Oncogene 2002, 21, 4900-4907.
95. Menendez, J.A.; Mehmi, I.; Lupu, R. Trastuzumab in combination with heregulin-activated Her-2 (ErbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J. Clin. Oncol. 2006, 24, 3735-3746.
96. Raj, E.H.; Skinner, A.; Mahji, U.; Nirmala, K.N.; Ravichandran, K.; Shanta, V.; Hurst, H.C.; Gullick, W.J.; Rajkumar, T. Neuregulin 1-alpha expression in locally advanced breast cancer. Breast (Edinburgh, Scotland) 2001, 10, 41-45.
97. Cheng, L.; Zha, Z.; Lang, B.; Liu, J.; Yao, X. Heregulin-beta1 promotes metastasis of breast cancer cell line SKBR3 through upregulation of snail and induction of epithelial-mesenchymal transition. Cancer Lett. 2009, 280, 50-60.
98. Kim, J.; Jeong, H.; Lee, Y.; Kim, C; Kim, H.; Kim, A. HRG-beta1-driven ErbB3 signaling induces epithelial-mesenchymal transition in breast cancer cells. BMC Cancer 2013, 13, 383.
99. Adam, L.; Vadlamudi, R.; Kondapaka, S.B.; Chernoff, J.; Mendelsohn, J.; Kumar, R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J. Biol. Chem. 1998, 273, 28238–28246.
100. Talukder, A.H.; Adam, L.; Raz, A.; Kumar, R. Heregulin regulation of autocrine motility factor expression in human tumor cells. Cancer Res. 2000, 60, 474–480.
101. Cress, W.D.; Seto, E. Histone deacetylases, transcriptional control, and cancer J. Cell Physiol. 2000, 184, 1–16.
102. Loeb, J.A.; Fischbach, G.D. Aria can be released from extracellular matrix through cleavage of a heparin-binding domain. J. Cell Biol. 1995, 130, 127–135.
103. Ferguson, K.M.; Berger, M.B.; Mendrola, J.M.; Cho, H.S.; Leahy, D.J.; Lemmon, M.A. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell 2003, 11, 507–517.
104. Yarden, Y.; Sliwkowski, M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2, 127–137.
105. Carraway, K.L., 3rd; Weber, J.L.; Unger, M.J.; Ledesma, J.; Yu, N.; Gassmann, M.; Lai, C. Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases. Nature 1997, 387, 512–516.
106. Hynes, N.E.; Lane, H.A. ErbB receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5, 341–354.
107. Marmor, M.D.; Yarden, Y. Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene 2004, 23, 2057–2070.
108. Yaffe, M.B. Phosphotyrosine-binding domains in signal transduction. Nat. Rev. Mol. Cell Biol. 2002, 3, 177–186.
109. Carpenter, G. ErbB-4: Mechanism of action and biology. Exp. Cell Res. 2003, 284, 66–77.
110. Citri, A.; Skaria, K.B.; Yarden, Y. The deaf and the dumb: The biology of ErbB-2 and ErbB-3. Exp. Cell Res. 2003, 284, 54–65.
111. Jorissen, R.N.; Walker, F.; Pouliot, N.; Garrett, T.P.; Ward, C.W.; Burgess, A.W. Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp. Cell Res. 2003, 284, 31–53.
112. Mendelsohn, J.; Baselga, J. The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19, 6550–6565.
113. Wong, A.J.; Ruppert, J.M.; Bigner, S.H.; Grzeschik, C.H.; Humphrey, P.A.; Bigner, D.S.; Vogelstein, B. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. USA 1992, 89, 2965–2969.
114. Mitsudomi, T.; Yatabe, Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 2010, 277, 301–308.
115. De Jong, K.P.; Stellema, R.; Karrenbeld, A.; Koudstaal, J.; Gouw, A.S.; Sluiter, W.J.; Peeters, P.M.; Slooff, M.J.; de Vries, E.G. Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology 1998, 28, 971–979.
116. Douziech, N.; Calvo, E.; Laine, J.; Morisset, J. Activation of map kinases in growth responsive pancreatic cancer cells. Cell Signal. 1999, 11, 591–602.
117. Mendelsohn, J. The epidermal growth factor receptor as a target for cancer therapy. Endocr. Relat. Cancer 2001, 8, 3–9.
118. Sasaki, T.; Hiroki, K.; Yamashita, Y. The role of epidermal growth factor receptor in cancer metastasis and microenvironment. Biomed. Res. Int. 2013, doi:10.1155/2013/546318.
119. Tzahar, E.; Waterman, H.; Chen, X.; Levkowitz, G.; Karunagaran, D.; Lavi, S.; Ratzkin, B.J.; Yarden, Y. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell Biol. 1996, 16, 5276–5287.
120. Muss, H.B.; Thor, A.D.; Berry, D.A.; Kute, T.; Liu, E.T.; Koerner, F.; Cirrincione, C.T.; Budman, D.R.; Wood, W.C.; Barcos, M. et al. C-ErbB-2 expression and response to adjuvant therapy in women with node-positive early breast Cancer. N. Engl. J. Med. 1994, 330, 1260–1266.
121. Slamon, D.J.; Godolphin, W.; Jones, L.A.; Holt, J.A.; Wong, S.G.; Keith, D.E.; Levin, W.J.; Stuart, S.G.; Udove, J.; Ullrich, A. et al. Studies of the Her-2/NEU proto-oncogene in human breast and ovarian Cancer. Science 1989, 244, 707–712.
122. Mimnaugh, E.G.; Chavany, C.; Neckers, L. Polyubiquitination and proteasomal degradation of the p185c-ErbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J. Biol. Chem. 1996, 271, 22796–22801.
123. Xu, W.; Mimnaugh, E.; Rosser, M.F.; Nicchitta, C.; Marcu, M.; Yarden, Y.; Neckers, L. Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein hsp90. J. Biol. Chem. 2001, 276, 3702–3708.
124. Citri, A.; Kochupurakkal, B.S.; Yarden, Y. The achilles heel of ErbB-2/Her2: Regulation by the hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 2004, 3, 51–60.
125. Sidera, K.; Gaitanou, M.; Stellas, D.; Matsas, R.; Patsavoudi, E. A critical role for hsp90 in cancer cell invasion involves interaction with the extracellular domain of Her-2. J. Biol. Chem. 2008, 283, 2031–2041.
126. Garrett, T.P.; McKern, N.M.; Lou, M.; Elleman, T.C.; Adams, T.E.; Lovrecz, G.O.; Kofler, M.; Jorissen, R.N.; Nice, E.C.; Burgess, A.W. et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other erbb receptors. Mol. Cell 2003, 11, 495–505.
127. Roskoski, R., Jr. The ErbB/Her receptor protein-tyrosine kinases and cancer. Biochem. Biophys. Res. Commun. 2004, 319, 1–11.
128. Sachdev, D. Regulation of breast cancer metastasis by IGF signaling. J. Mammary Gland Biol. Neoplasia 2008, 13, 431–441.
129. Chitnis, M.M.; Yuen, J.S.; Protheroe, A.S.; Pollak, M.; Macaulay, V.M. The type 1 insulin-like growth factor receptor pathway. Clin. Cancer Res. 2008, 14, 6364–6370.
130. Lopez, T.; Hanahan, D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2002, 1, 339–353.
131. Sachdev, D.; Zhang, X.; Matise, I.; Gaillard-Kelly, M.; Yee, D. The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene 2010, 29, 251–262.
132. Jackson, J.G.; Zhang, X.; Yoneda, T.; Yee, D. Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene 2001, 20, 7318–7325.
133. Kato, H.; Faria, T.N.; Stannard, B.; Roberts, C.T., Jr.; LeRoith, D. Essential role of tyrosine residues 1131, 1135, and 1136 of the insulin-like growth factor-I (IGF-I) receptor in IGF-I action. Mol. Endocrinol. 1994, 8, 40-50.
134. Yoneda, T.; Williams, P.J.; Hiraga, T.; Niewolna, M.; Nishimura, R. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J. Bone Miner. Res. 2001, 16, 1486-1495.
135. Hiraga, T.; Myoui, A.; Hashimoto, N.; Sasaki, A.; Hata, K.; Morita, Y.; Yoshikawa, H.; Rosen, C.J.; Mundy, G.R.; Yoneda, T. Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res. 2012, 72, 4238-4249.
136. Saldana, S.M.; Lee, H.H.; Lowery, F.J.; Khotskaya, Y.B.; Xia, W.; Zhang, C; Chang, S.S.; Chou, C.K.; Steeg, P.S.; Yu, D. et al. Inhibition of type I insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis. PLOS ONE 2013, 8, e73406.
137. Min, K.W.; Kim, D.H.; Do, S.I.; Kim, K.; Lee, H.J.; Chae, S.W.; Sohn, J.H.; Pyo, J.S.; Oh, Y.H.; Kim, W.S. et al. Expression patterns of stromal MMP-2 and tumoural MMP-2 and -9 are significant prognostic factors in invasive ductal carcinoma of the breast. Apmis 2014, 122, 1196-1206.
138. Stellas, D.; Patsavoudi, E. Inhibiting matrix metalloproteinases, an old story with new potentials for cancer treatment. Anticancer Agents Med. Chem. 2012, 12, 707–717.
139. Galis, Z.S.; Khatri, J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ. Res. 2002, 90, 251-262.
140. Zuo, J.H.; Zhu, W.; Li, MY.; Li, X.H.; Yi, H.; Zeng, G.Q.; Wan, X.X.; He, Q.Y.; Li, J.H.; Qu, J.Q. et al. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing emt-like phenotype change and MMP-9-mediated degradation of E-cadherin. J. Cell Biochem. 2011, 112, 2508-2517.
141. Eustace, B.K.; Jay, D.G. Extracellular roles for the molecular chaperone, hsp90. Cell Cycle 2004, 3, 1098-1100.
142. Stellas, D.; El Hamidieh, A.; Patsavoudi, E. Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell Biol. 2010, doi: 10.1186/1471-2121-1111-1151.
143. Fedarko, N.S.; Jain, A.; Karadag, A.; Fisher, L.W. Three small integrin binding ligand n-linked glycoproteins (siblings) bind and activate specific matrix metalloproteinases. FASEB. J. 2004, 18, 734-736.
144. Murphy, D.A.; Courtneidge, S.A. The “ins” and “outs” of podosomes and invadopodia: Characteristics, formation and function. Nat. Rev. Mol. Cell Biol. 2011, 12, 413-426.
145. Jacob, A.; Jing, J.; Lee, J.; Schedin, P.; Gilbert, S.M.; Peden, A.A.; Junutula, J.R.; Prekeris, R. Rab40b regulates trafficking of MMP2 and MMP9 during invadopodia formation and invasion of breast cancer cells. J. Cell Sci. 2013, 126, 4647-4658.
146. Pfeffer, S.R. Rab gtpases: Specifying and deciphering organelle identity and function. Trends Cell Biol. 2001, 11, 487-491.
147. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2, 161-174.
148. Sun, Z.; Wang, S.; Zhao, R.C. The roles of mesenchymal stem cells in tumor inflammatory microenvironment. J. Hematol. Oncol. 2014, doi: 10.1186/1756-8722-1187-1114.
149. Campbell, N.E.; Kellenberger, L.; Greenaway, J.; Moorehead, R.A.; Linnerth-Petrik, N.M.; Petrik, J. Extracellular matrix proteins and tumor angiogenesis. J. Oncol. 2010, doi:10.1155/2010/586905.
150. Hawinkels, L.J.; Zuidwijk, K.; Verspaget, H.W.; de Jonge-Muller, E.S.; van Duijn, W.; Ferreira, V.; Fontijn, R.D.; David, G.; Hommes, D.W.; Lamers, C.B. et al. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. Eur. J. Cancer 2008, 44, 1904–1913.
151. Hollborn, M.; Stathopoulos, C.; Steffen, A.; Wiedemann, P.; Kohen, L.; Bringmann, A. Positive feedback regulation between MMP-9 and VEGF in human RPE cells. Invest. Ophthalmol. Vis. Sci. 2007, 48, 4360–4367.
152. Lee, S.; Jilani, S.M.; Nikolova, G.V.; Carpizo, D.; Iruela-Arispe, M.L. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J. Cell Biol. 2005, 169, 681–691.
153. Malfroy, B.; Kuang, W.J.; Seeburg, P.H.; Mason, A.J.; Schofield, P.R. Molecular cloning and amino acid sequence of human enkephalinase (neutral endopeptidase). FEBS Lett. 1988, 229, 206–210.
154. Ishimaru, F.; Mari, B.; Shipp, M.A. The type 2 CD10/neutral endopeptidase 24.11 promoter: Functional characterization and tissue-specific regulation by CBF/NF-Y isoforms. Blood 1997, 89, 4136–4145.
155. Sumitomo, M.; Shen, R.; Walburg, M.; Dai, J.; Geng, Y.; Navarro, D.; Boileau, G.; Papandreou, C.N.; Giancotti, F.G.; Knudsen, B. et al. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. J. Clin. Invest. 2000, 106, 1399–1407.
156. Shipp, M.A.; Stefano, G.B.; Switzer, S.N.; Griffin, J.D.; Reinherz, E.L. CD10 (CALLA)/neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regulated by neutrophil activation. Blood 1991, 78, 1834–1841.
157. Bachelard-Cascales, E.; Chapellier, M.; Delay, E.; Pochon, G.; Voeltzel, T.; Puisieux, A.; Caron de Fromentel, C.; Maguer-Satta, V. The CD10 enzyme is a key player to identify and regulate human mammary stem cells. Stem Cells 2010, 28, 1081–1088.
158. Stingl, J.; Raouf, A.; Emerman, J.T.; Eaves, C.J. Epithelial progenitors in the normal human mammary gland. J. Mammary Gland Biol. Neoplasia 2005, 10, 49–59.
159. Sunday, M.E.; Hua, J.; Torday, J.S.; Reyes, B.; Shipp, M.A. CD10/neutral endopeptidase 24.11 in developing human fetal lung. Patterns of expression and modulation of peptide-mediated proliferation. J. Clin. Invest. 1992, 90, 2517–2525.
160. Buhring, H.J.; Battula, V.L.; Treml, S.; Schewe, B.; Kanz, L.; Vogel, W. Novel markers for the prospective isolation of human msc. Ann. N. Y. Acad. Sci. 2007, 1106, 262–271.
161. Terauchi, M.; Kajiyama, H.; Shibata, K.; Ino, K.; Mizutani, S.; Kikkawa, F. Anti-progressive effect of neutral endopeptidase 24.11 (NEP/CD10) on cervical carcinoma in vitro and in vivo. Oncology 2005, 69, 52–62.
162. Tokuhara, T.; Adachi, M.; Hashida, H.; Ishida, H.; Taki, T.; Higashiyama, M.; Kodama, K.; Tachibana, S.; Sasaki, S.; Miyake, M. Neutral endopeptidase/CD10 and aminopeptidase N/CD13 gene expression as a prognostic factor in non-small cell lung Cancer. Jpn. J. Thorac. Cardiovasc. Surg. 2001, 49, 489–496.
163. Ikenaga, N.; Ohuchida, K.; Mizumoto, K.; Cui, L.; Kayashima, T.; Morimatsu, K.; Moriyama, T.; Nakata, K.; Fujita, H.; Tanaka, M. CD10+ pancreatic stellate cells enhance the progression of pancreatic cancer. Gastroenterology 2010, 139, 1041–1051.
164. Maguer-Satta, V.; Besancon, R.; Bachelard-Cascales, E. Concise review: Neutral endopeptidase (CD10): A multifaceted environment actor in stem cells, physiological mechanisms, and cancer. Stem Cells 2011, 29, 389–396.
165. Omran, O.M. CD10 and E-cad expression in urinary bladder urothelial and squamous cell carcinoma. J. Environ. Pathol. Toxicol. Oncol. 2012, 31, 203–212.
166. Kim, H.S.; Kim, G.Y.; Kim, Y.W.; Park, Y.K.; Song, J.Y.; Lim, S.J. Stromal CD10 expression and relationship to the E-cadherin/beta-catenin complex in breast carcinoma. Histopathology 2010, 56, 708–719.
167. Makretsov, N.A.; Hayes, M.; Carter, B.A.; Dabiri, S.; Gilks, C.B.; Huntsman, D.G. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod. Pathol. 2007, 20, 84–89.
168. Lee, K.W.; Kim, J.H.; Han, S.; Sung, C.O.; Do, I.G.; Ko, Y.H.; Um, S.H.; Kim, S.H. Twist1 is an independent prognostic factor of esophageal squamous cell carcinoma and associated with its epithelial-mesenchymal transition. Ann. Surg. Oncol. 2012, 19, 326–335.
169. Lee, K.W.; Sung, C.O.; Kim, J.H.; Kang, M.; Yoo, H.Y.; Kim, H.H.; Um, S.H.; Kim, S.H. CD10 expression is enhanced by twist1 and associated with poor prognosis in esophageal squamous cell carcinoma with facilitating tumorigenicity in vitro and in vivo. Int. J. Cancer 2015, 136, 310–321.
170. Sidera, K.; Samiotaki, M.; Yfanti, E.; Panayotou, G.; Patsavoudi, E. Involvement of cell surface hsp90 in cell migration reveals a novel role in the developing nervous system. J. Biol. Chem. 2004, 279, 45379–45388.
171. Becker, B.; Multhoff, G.; Farkas, B.; Wild, P.J.; Landthaler, M.; Stolz, W.; Vogt, T. Induction of hsp90 protein expression in malignant melanomas and melanoma metastases. Exp. Dermatol. 2004, 13, 27–32.
172. Stellas, D.; Karameris, A.; Patsavoudi, E. Monoclonal antibody 4C5 immunostains human melanomas and inhibits melanoma cell invasion and metastasis. Clin. Cancer Res. 2007, 13, 1831–1838.
173. Tsutsumi, S.; Beebe, K.; Neckers, L. Impact of heat-shock protein 90 on cancer metastasis. Future Oncol. 2009, 5, 679–688.
174. Yang, Y.; Rao, R.; Shen, J.; Tang, Y.; Fiskus, W.; Nechtman, J.; Atadja, P.; Bhalla, K. Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Res. 2008, 68, 4833–4842.
175. Li, W.; Sahu, D.; Tsen, F. Secreted heat shock protein-90 (hsp90) in wound healing and Cancer. Biochim. Biophys. Acta 2012, 1823, 730–741.
176. Stivarou, T.; Vartzi, G.; Thomaidou, D.; Patsavoudi, E. Hellenic Pasteur Institute, Athens, Greece, 2015, Personal observations.
177. Pearl, L.H. Hsp90 and cdc37—A chaperone cancer conspiracy. Curr. Opin. Genet. Dev. 2005, 15, 55–61.
178. Smith, J.R.; Workman, P. Targeting cdc37: An alternative, kinase-directed strategy for disruption of oncogenic chaperoning. Cell Cycle 2009, 8, 362–372.
179. Silverstein, A.M.; Grammatikakis, N.; Cochran, B.H.; Chinkers, M.; Pratt, W.B. P50(cdc37) binds directly to the catalytic domain of raf as well as to a site on hsp90 that is topologically adjacent to the tetratricopeptide repeat binding site. J. Biol. Chem. 1998, 273, 20090–20095.
180. Kimura, Y.; Rutherford, S.L.; Miyata, Y.; Yahara, I.; Freeman, B.C.; Yue, L.; Morimoto, R.I.; Lindquist, S. Cdc37 is a molecular chaperone with specific functions in signal transduction. Genes Dev. 1997, 11, 1775–1785.
181. Hartson, S.D.; Irwin, A.D.; Shao, J.; Scroggins, B.T.; Volk, L.; Huang, W.; Matts, R.L. P50(cdc37) is a nonexclusive hsp90 cohort which participates intimately in hsp90-mediated folding of immature kinase molecules. Biochemistry 2000, 39, 7631–7644.
182. El Hamidieh, A.; Grammatikakis, N.; Patsavoudi, E. Cell surface cdc37 participates in extracellular hsp90 mediated cancer cell invasion. PLOS ONE 2012, 7, e42722.
183. Fayard, B.; Bianchi, F.; Dey, J.; Moreno, E.; Djaffer, S.; Hynes, N.E.; Monard, D. The serine protease inhibitor protease nexin-1 controls mammary cancer metastasis through LRP-1-mediated MMP-9 expression. Cancer Res. 2009, 69, 5690–5698.
184. Song, H.; Li, Y.; Lee, J.; Schwartz, A.L.; Bu, G. Low-density lipoprotein receptor-related protein 1 promotes cancer cell migration and invasion by inducing the expression of matrix metalloproteinases 2 and 9. Cancer Res. 2009, 69, 879–886.
185. Staudt, N.D.; Jo, M.; Hu, J.; Bristow, J.M.; Pizzo, D.P.; Gaultier, A.; VandenBerg, S.R.; Gonias, S.L. Myeloid cell receptor LRP1/CD91 regulates monocyte recruitment and angiogenesis in tumors. Cancer Res. 2013, 73, 3902–3912.
186. Tsen, F.; Bhatia, A.; O’Brien, K.; Cheng, C.F.; Chen, M.; Hay, N.; Stiles, B.; Woodley, D.T.; Li, W. Extracellular heat shock protein 90 signals through subdomain II and the npvy motif of LRP-1 receptor to AKT1 and AKT2: A circuit essential for promoting skin cell migration in vitro and wound healing in vivo. Mol. Cell Biol. 2013, 33, 4947–4959.
187. Montel, V.; Gaultier, A.; Lester, R.D.; Campana, W.M.; Gonias, S.L. The low-density lipoprotein receptor-related protein regulates cancer cell survival and metastasis development. Cancer Res. 2007, 67, 9817–9824.
188. Gopal, U.; Bohonowych, J.E.; Lema-Tome, C.; Liu, A.; Garrett-Mayer, E.; Wang, B.; Isaacs, J.S. A novel extracellular hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. PLOS ONE 2011, 6, e17649.
189. Wykosky, J.; Debinski, W. The EphA2 receptor and ephrina1 ligand in solid tumors: Function and therapeutic targeting. Mol. Cancer Res. 2008, 6, 1795–1806.
190. Dedieu, S.; Langlois, B.; Devy, J.; Sid, B.; Henriet, P.; Sartelet, H.; Bellon, G.; Emonard, H.; Martiny, L. LRP-1 silencing prevents malignant cell invasion despite increased pericellular proteolytic activities. Mol. Cell Biol. 2008, 28, 2980–2995.